ReviewDiscover oncology2025
Progress of the application of spatially fractionated radiation therapy in palliative treatment of tumors.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis of global research trends in spatially fractionated radiotherapy.Frontiers in oncology · 2026Pooled it
- Exploratory personalized radiobiological modeling of bystander and immune effects to inform SFRT-SBRT scheduling.Medical physics · 2026Article
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Spatially fractionated radiation therapy (SFRT): a scoping review of dosimetric and biological evidence supporting a valley dose-driven translational framework.Radiation oncology (London, England) · 2026Article
- Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.Molecular cancer · 2026Review
- Rapid Hemostasis and Significant Tumor Regression in Ulcerative Breast Cancer Via Combined Modified Lattice Radiotherapy and Systemic Therapy: A Case Report.Breast cancer : basic and clinical research · 2026Article
- Phenotypic risk factors linked to acute radiation-induced toxicities: a phenome-wide Mendelian randomization study of 12,042 cancer patients.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
backgroundMalignant tumors pose a serious threat to human health. As tumor volume increases, conventional external beam radiation therapy (cEBRT) faces challenges in tumor control and normal tissue toxicity. Spatially fractionated radiation therapy (SFRT) has emerged as an alternative approach. MATERIALS AND
methodsThis article reviews the history of SFRT, including kilovolt X-ray based GRID, megavolt X-ray based GRID, MLC-shaped GRID, LATTICE radiation therapy (LRT), Bragg-peak based SFRT, microbeam, minibeam, SBRT-PATHY, and ISPART. It also explores its radiobiological mechanisms, such as immunomodulation, bystander and abscopal effects, and vascular response. Clinical studies of SFRT in palliative tumor treatment are summarized, and its limitations and future directions are discussed.
resultsSFRT has shown high symptom remission rates, significant target volume reduction, and even tumor control and long-term survival in some cases across various tumor types. However, it has limitations like lack of standardized dosimetric parameters, complex implementation, small-scale clinical studies, and uncertain immunomodulatory potential.
conclusionDespite limitations, SFRT shows promise as a palliative radiation therapy technique. Future large-scale, multi-center clinical trials are needed to standardize dosimetric parameters, clarify immunomodulatory mechanisms, and simplify the technology for wider application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.